The Office of Medical Policy (OMP) is offering a grant to convene discussions on medical policy issues impacting drug development. This grant aims to create a public forum with various stakeholders to identify key issues in policy development, without seeking advice on regulatory actions or aiming for consensus. The focus is on gathering expert opinions while ensuring transparency and making information available to the public. Applicants have until Jun 02, 2014, to apply for this grant.
Opportunity ID: 253194
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | RFA-FD-14-003 |
| Funding Opportunity Title: | Convener of Discussions on Medical Policy Issues Impacting Drug Development |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Education Health Science and Technology and other Research and Development |
| Category Explanation: | – |
| Expected Number of Awards: | 5 |
| Assistance Listings: | 93.103 — Food and Drug Administration_Research |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Mar 30, 2014 |
| Last Updated Date: | – |
| Original Closing Date for Applications: | Jun 02, 2014 |
| Current Closing Date for Applications: | Jun 02, 2014 |
| Archive Date: | Jul 02, 2014 |
| Estimated Total Program Funding: | $600,000 |
| Award Ceiling: | $600,000 |
| Award Floor: | $550,000 |
Eligibility
| Eligible Applicants: | Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education |
| Additional Information on Eligibility: | – |
Additional Information
| Agency Name: | Food and Drug Administration |
| Description: | The Office of Medical Policy (OMP) provides CDER oversight and leadership in the development of medical policy, procedures, and policy initiatives pertaining to drug development, drug approval, bioresearch monitoring, human subject protection and post market surveillance processes. When developing and implementing policy, a key step is often to create a broad public forum with a variety of stakeholders to identify key issues that will need to be addressed before, during, and after implementation of any initiative. These discussions can help focus many of the policy and procedural needs of an evolving initiative. The goal of such meetings is not to obtain advice relating to regulatory actions or to make decisions. Nor is the goal to reach a consensus among the participants on any of the issues discussed. Rather, it is to hear the opinions of experts in the field and other individual stakeholders.
In addition, it is important to maintain transparency. The goal of these meetings is to be as inclusive as possible, while still limiting participation to a number that supports the meetings goals and objectives. However, it is important to ensure that information from these meetings and working groups must be described, managed, and made available to the public using a transparent and open approach. |
| Link to Additional Information: | NIH Guide for Grants and Contracts |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
Gladys Melendez-Bohler
Grants Management Specialist Phone 301-827-7175 Email:gladys.bohler@fda.hhs.gov |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
Folder 253194 Full Announcement-1 -> rfa-fd-14-003 convener of discussions on medical policy issues impacting drug development (u13).pdf
Packages
| Agency Contact Information: | Gladys Melendez-Bohler Grants Management Specialist Phone 301-827-7175 Email: gladys.bohler@fda.hhs.gov |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| 93.103 | ADOBE-FORMS-C | RFA-FDA-14-003 | PKG00194629 | Apr 05, 2014 | Jun 02, 2014 | View |
Package 1
Mandatory forms
253194 RR_SF424_2_0-2.0.pdf
253194 PHS398_ResearchPlan_2_0-2.0.pdf
253194 PHS398_CoverPageSupplement_2_0-2.0.pdf
253194 RR_Budget_1_3-1.3.pdf
253194 RR_KeyPersonExpanded_2_0-2.0.pdf
253194 RR_OtherProjectInfo_1_3-1.3.pdf
253194 PerformanceSite_2_0-2.0.pdf
Optional forms
253194 PlannedReport-1.0.pdf
253194 PHS398_CumulativeInclusionReport-1.0.pdf
253194 RR_SubawardBudget30_1_3-1.3.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
